Cadrenal Therapeutics, Inc. (CVKD)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | (2.7M) | (3.1M) | (2.5M) | (3.3M) |
| Net Income | (2.7M) | (3.0M) | (2.5M) | (3.3M) |
| Diluted EPS | $-1.31 | N/A | $-1.04 | $-1.14 |
Annual Financials
| Metric | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 |
| Operating Income | (7.6M) | (11.0M) | (13.5M) |
| Net Income | (8.4M) | (10.7M) | (13.2M) |
| Diluted EPS | $-9.29 | $-8.73 | $-6.64 |